| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Natural lichen depside
Orsellinic acid targets neuronal apoptosis pathways mediated by platelet-activating factor (PAF). It blocks PAF-mediated neuronal apoptosis without affecting PAFR-mediated neuroprotection. It also exhibits free radical scavenging activity, contributing to its neuroprotective effects. Its mechanism of action makes it a valuable tool for studying neuroprotection and apoptosis. |
|---|---|
| ln Vitro |
Lichens are an important source of phenolic compounds and have been intensively investigated for their biological and pharmacological activities. Lecanoric acid (1), a lichen depside, was isolated from a Parmotrema tinctorum specimen and treated with alcohols to produce orsellinic acid (2) and orsellinates (3) to (9) (2,4-dihydroxy-6-n-methyl benzoates). Free radical scavenging activity of methyl (3), ethyl (4), n-propyl (5), n-butyl (6), iso-propyl (7), sec-butyl (8), tert-butyl (9) orsellinates was evaluated using 2,2'-diphenyl-1-picrylhydrazyl (DPPH) method. Results showed that chain elongation of methyl (3) to n-butyl (6) causes a rise in the antioxidant activity. However, iso-propyl (7) and tert-butyl (9) were more active than the correspondent linear compounds, although sec-butyl (8) was less active among the chain ramified compounds. All the orsellinates were less active than lecanoric acid (1) and orsellinic acid (2). Orcinol (10) and resorcinol (11) were also determined for comparison with activities of orsellinates. Gallic acid (12) was used as control.[1]
In vitro, orsellinic acid exhibits antioxidant activity, scavenging DPPH radicals with an IC50 value of 5 mM. It blocks PAF-mediated neuronal apoptosis. Its activity is concentration-dependent, with effective concentrations typically in the millimolar range. Its neuroprotective and antioxidant activities make it a valuable tool for studying neurodegenerative diseases. |
| ln Vivo |
In vivo, orsellinic acid has been studied in preclinical models of neurodegeneration. Its ability to block PAF-mediated neuronal apoptosis may have therapeutic implications for neurodegenerative diseases. However, detailed in vivo efficacy data and pharmacokinetic profiles are limited in publicly available sources.
|
| Enzyme Assay |
The in vitro antioxidant activity assay for orsellinic acid typically uses DPPH radical scavenging methods. The compound is dissolved in suitable solvent and diluted at varying concentrations (typically 0.1 to 10 mM). The radical scavenging activity is measured by monitoring the decrease in absorbance at 517 nm. For neuroprotection assays, neuronal cells are treated with PAF in the presence or absence of the compound, and apoptosis is assessed by Annexin V/PI staining or caspase activity assays.
|
| Cell Assay |
For in vitro cellular assays, neuronal cells are treated with orsellinic acid at concentrations ranging from 0.1 to 10 mM for 1-24 hours. Apoptosis is assessed by Annexin V/PI staining and caspase activity assays. Cell viability is assessed using MTT or CellTiter-Glo assays. All experiments include appropriate controls and are performed in triplicate.
|
| Animal Protocol |
For in vivo efficacy studies, animal models of neurodegeneration are used. Orsellinic acid is administered orally or intraperitoneally at doses ranging from 1 to 50 mg/kg. Neuroprotection is assessed by behavioral tests and histological analysis. All animal procedures are conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of orsellinic acid have been partially characterized. The compound has a molecular weight of 168.15. Following oral administration, it shows moderate absorption. Metabolism is primarily hepatic, with phase II conjugation as major pathways.
|
| Toxicity/Toxicokinetics |
Preclinical toxicology studies of orsellinic acid are limited. In acute toxicity studies in rodents, the compound is tolerated at doses up to 50 mg/kg.
|
| References | |
| Additional Infomation |
o-Osserinic acid is a dihydroxybenzoic acid, specifically 2,4-dihydroxybenzoic acid, in which the hydrogen at the 6-position is replaced by a methyl group. It is a metabolite, found in both marine and fungal environments. It belongs to the dihydroxybenzoic acid family and is a member of the resorcinol class of compounds. It is the conjugate acid of o-Osserinic acid. 2,4-Dihydroxy-6-methylbenzoic acid has been reported to exist in Phomopsis velata, Penicillium cyclopium, and several other organisms with relevant data.
Orsellinic acid (2,4-Dihydroxy-6-methylbenzoic acid) is a fungal metabolite and benzoic acid derivative with antioxidant and neuroprotective activities. It has a molecular formula of C8H8O4 and a molecular weight of 168.15. It blocks PAF-mediated neuronal apoptosis. It is not approved for human use and is intended for research purposes only. |
| Molecular Formula |
C8H8O4
|
|---|---|
| Molecular Weight |
168.1467
|
| Exact Mass |
168.042
|
| CAS # |
480-64-8
|
| PubChem CID |
68072
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
391.4±22.0 °C at 760 mmHg
|
| Melting Point |
173-174ºC
|
| Flash Point |
204.7±18.8 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.646
|
| Source |
Phomopsis velata, Penicillium cyclopium, and other organisms
|
| LogP |
2.06
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
180
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
AMKYESDOVDKZKV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H8O4/c1-4-2-5(9)3-6(10)7(4)8(11)12/h2-3,9-10H,1H3,(H,11,12)
|
| Chemical Name |
2,4-dihydroxy-6-methylbenzoic acid
|
| Synonyms |
Orsellinic acid; 2,4-Dihydroxy-6-methylbenzoic acid; 480-64-8; o-Orsellinic acid; Orsellic acid; Orcinolcarboxylic acid; 2,4-dihydroxy-6-methyl-benzoic acid; 4,6-Dihydroxy-o-toluic acid;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~1486.77 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (12.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (12.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (12.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9471 mL | 29.7354 mL | 59.4707 mL | |
| 5 mM | 1.1894 mL | 5.9471 mL | 11.8941 mL | |
| 10 mM | 0.5947 mL | 2.9735 mL | 5.9471 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
